Prostate Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas

DelveInsight's, "Prostate Cancer - Pipeline Insight, 2025," report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 80 leading companies are actively engaged in the development of more than 80 therapeutic candidates for the treatment of prostate cancer.

Prostate Cancer Overview:

Prostate cancer develops when cells within the prostate gland begin to grow uncontrollably. The prostate, a male-specific gland, contributes to the production of seminal fluid. This type of cancer is primarily driven by genetic mutations that alter DNA. It is often diagnosed at a later stage when symptoms become more evident, though early screening can detect it before noticeable signs emerge. Because of the prostate's location near the urethra and bladder, urinary issues are a frequent symptom as the tumor progresses. Depending on the size and position of the tumor, it can press against or constrict the urethra, leading to symptoms such as painful or burning urination, difficulty starting or stopping urination, frequent nighttime urination, reduced bladder control, and a weaker urine stream.

Request for a detailed insights report on Prostate Cancer pipeline insights [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Prostate Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Prostate Cancer Therapeutics Market.

Key Takeaways from the Prostate Cancer Pipeline Report

*
DelveInsight's Prostate Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Prostate Cancer treatment.

*
In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx Registered and atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.

*
In the same month, Foundation Medicine received FDA approval for FoundationOne Registered CDx and Liquid CDx as companion diagnostics for Lynparza Registered in BRCA-mutated mCRPC.

*
In July 2024, the ARANOTE trial demonstrated that NUBEQA Registered combined with androgen deprivation therapy (ADT) significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).

*
Also in July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for mCRPC.

*
In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 combined with Abiraterone for mCRPC.

*
In May 2024, Fusion Pharmaceuticals initiated the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.

*
In April 2024, Astellas Pharma received European approval for XTANDI Trademark in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).

*
In the same month, FibroGen announced positive Phase 1 trial results for FG-3246 in mCRPC.

*
On February 12, 2024, BioXcel Therapeutics, Inc. revealed that the FDA granted Fast Track designation for BXCL701 with a checkpoint inhibitor (CPI) to treat metastatic small cell neuroendocrine prostate cancer (SCNC) in patients progressing on chemotherapy, allowing for expedited development and review.

*
On November 16, 2023, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.

*
Key Prostate Cancer companies such as Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd., and others are evaluating new drugs for Prostate Cancer to improve the treatment landscape.

*
Promising Prostate Cancer pipeline therapies in various stages of development include Niraparib, ZEN 3694, Ladiratuzumab vedotin, FOR46, REGN5678, and others.

Prostate Cancer Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Prostate Cancer Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Prostate Cancer market.

Download our free sample page report on Prostate Cancer pipeline insights [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Prostate Cancer Emerging Drugs

*
Niraparib: Janssen Research & Development

*
ZEN 3694: Zenith Epigenetics

*
Ladiratuzumab vedotin: Seagen

*
FOR46: Fortis Therapeutics

*
REGN5678: Regeneron Pharmaceuticals

Prostate Cancer Companies

Over 140 leading companies are actively developing treatments for prostate cancer. Among them, Janssen Research & Development stands out with some of the most advanced drug candidates, currently undergoing Phase III clinical trials.

DelveInsight's report covers around 80+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Prostate Cancer Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Prostate Cancer Therapies and Key Companies: Prostate Cancer Clinical Trials and advancements [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Prostate Cancer Pipeline Therapeutic Assessment

- Prostate Cancer Assessment by Product Type

- Prostate Cancer By Stage

- Prostate Cancer Assessment by Route of Administration

- Prostate Cancer Assessment by Molecule Type

Download Prostate Cancer Sample report to know in detail about the Prostate Cancer treatment market @ Prostate Cancer Therapeutic Assessment [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Prostate Cancer Current Treatment Patterns

4. Prostate Cancer - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Prostate Cancer Late-Stage Products (Phase-III)

7. Prostate Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Prostate Cancer Discontinued Products

13. Prostate Cancer Product Profiles

14. Prostate Cancer Key Companies

15. Prostate Cancer Key Products

16. Dormant and Discontinued Products

17. Prostate Cancer Unmet Needs

18. Prostate Cancer Future Perspectives

19. Prostate Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Prostate Cancer Pipeline Reports Offerings [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prostate-cancer-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-pfizer-janssen-pharmaceutical-point-biopharma-tavanta-therapeutics-exelixis-astellas]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.